Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05197413|
Recruitment Status : Completed
First Posted : January 19, 2022
Last Update Posted : January 19, 2022
|Condition or disease||Intervention/treatment||Phase|
|IBS - Irritable Bowel Syndrome Anxiety||Dietary Supplement: Arrae bloat supplement||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||35 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms|
|Actual Study Start Date :||September 1, 2021|
|Actual Primary Completion Date :||December 31, 2021|
|Actual Study Completion Date :||December 31, 2021|
Experimental: Arrae Bloat supplement
The "Bloat" capsules are a blend of 5 herbs and a fruit-based digestive enzyme that target the cause for IBS symptoms.
Dietary Supplement: Arrae bloat supplement
The supplement contains organic dandelion root extract, organic lemon balm herb top extract, organic peppermint leaf extract, organic bromelain, organic slippery elm inner bark extract. The capsule itself is made of cellulose, which is not a main active ingredient.
- Reduction in IBS symptoms (bloating, heartburn and gas) [ Time Frame: 4 weeks ]Survey-based assessment (0-5 scale with 0 being the lowest possible score and 5 being the highest) of changes in IBS symptoms between baseline and study intervention period.
- Reduction in anxiety symptoms [ Time Frame: 8 weeks ]Survey-based assessment (0-5 scale with 0 being the lowest possible score and 5 being the highest) of changes in anxiety symptoms between baseline and study intervention period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05197413
|United States, California|
|Santa Monica, California, United States, 90404|